EXCLI J EXCLI Journal 1611-2156 Leibniz Research Centre for Working Environment and Human Factors 2020-1226 10.17179/excli2020-1226 Doc620 Review article Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism Emamat Hadi 1 Ghalandari Hamid 2 Tangestani Hadith 3 4 Abdollahi Afsoun 5 Hekmatdoost Azita * 2 Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran Department of Nutrition, Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran Department of Nutrition Science, Purdue University, USA *To whom correspondence should be addressed: Azita Hekmatdoost, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, No 7, West Arghavan St., Farahzadi Blvd., Zip Code: 1981619573, P.O.Box: 19395-4741, Tehran, Iran; Tel: +98 21 22360658, Fax: +98 2122360657, E-mail: a_hekmat2000@yahoo.com 12 05 2020 2020 19 620 626 19 03 2020 05 05 2020 Copyright © 2020 Emamat et al. 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.

This article is available from https://www.excli.de/vol19/Hekmatdoost_12052020_proof.pdf

Non-alcoholic fatty liver disease (NAFLD) is a systemic and wide-spread disease characterized by accumulation of excess fat in the liver of people who drink little or no alcohol. Artificial sweeteners (ASs) or sugar substitutes are food additives that provide a sweet taste, and are also known as low-calorie or non-calorie sweeteners. Recently people consume increasingly more ASs to reduce their calorie intake. Gut microbiome is a complex ecosystem where 1014 microorganisms play several roles in host nutrition, bone mineralization, immune system regulation, xenobiotics metabolism, proliferation of intestinal cells, and protection against pathogens. A disruption in composition of the normal microbiota is known as ‘gut dysbiosis’ which may adversely affect body metabolism. It has recently been suggested that dysbiosis may contribute to the occurrence of NAFLD. The aim of the present study was to investigate the effects of ASs on the risk of NAFLD. The focus of this review is on microbiota changes and dysbiosis. Increasing evidence shows that ASs have a potential role in microbiota alteration and dysbiosis. We speculate that increased consumption of ASs can further raise the prevalence of NAFLD. However, further human studies are needed to determine this relationship definitively.

non-alcoholic fatty liver disease NAFLD microbiome microbiota artificial sweeteners
Introduction

Non-alcoholic fatty liver disease (NAFLD) is a systemic disease affecting several extra-hepatic organs and regulatory pathways (Byrne and Targher, 2015[8]). This disease consists of a series of events that will eventually lead to accumulation of excess fat in the liver of people who drink little or no alcohol (Chalasani et al., 2018[11]). NAFLD is a wide-spread disease and its current population-based prevalence is approximately 30 % to 40 % in men and 15 % to 20 % in women (Browning et al., 2004[7]). NAFLD is predicted to be the most common cause of liver transplantation by 2030 (Byrne and Targher, 2015[8]). NAFLD increases overall mortality by 57 % and doubles the risk of type 2 diabetes (Musso et al., 2011[34]) and chronic kidney disease (CKD) (Musso et al., 2014[35]). Obesity (Polyzos et al., 2019[37]), visceral ectopic fat accumulation (Ko et al., 2017[25]), adipose tissue inflammation (du Plessis et al., 2015[14]), type 2 diabetes (Bhatt and Smith, 2015[5]), nutrition and dietary pattern (Emamat et al., 2018[17]; Emamat, 2019[16]; George et al., 2018[20]; Mirmiran et al., 2017[31]), and intestinal dysbiosis (Saltzman et al., 2018[41], Kolodziejczyk et al., 2019[26]) are possible factors involved in the initiation and progression of NAFLD.

Artificial sweeteners (ASs) or sugar substitutes are food additives that provide a sweet taste, and are also known as low-calorie (e.g. sugar alcohols) or non-calorie (e.g. Aspartame, Acesulfame K, Sucralose and etc.) sweeteners (Lohner et al., 2017[28]). The G-proteins coupled receptors of taste on the tongue perceive the sense of sweetness. Sucrose provides a scale by which the sweetness of sweeteners is measured (Shallenberger and Acree, 1971[44]). Given that consumption of sugars, especially sucrose and glucose-fructose syrups, has dramatically increased worldwide with undesirable effects on body metabolic status, individuals consume increasingly more ASs to reduce their calorie intake (Stanhope, 2016[45]). Up to now, six ASs for foods and drinks including acesulfame potassium (acesulfame K), aspartame, neotame, saccharin, sucralose, and advantame have been approved by the FDA (2014[19]). Although the FDA and many national authorities have recognized that ASs are generally safe and well-tolerated, there is controversy about the effects of these sweeteners on human health (Lohner et al., 2017[28]). Ruanpeng et al. showed a significant association between ASs consumption and obesity in a meta-analysis (Ruanpeng et al., 2017[39]). According to a review study by Pearlman et al. in both animal models and humans, ASs may change the host microbiome, leading to decreased satiety, alteration in glucose homeostasis, increased calorie intake, weight gain and metabolic syndrome (Pearlman et al., 2017[36]).

Gut microbiome is a complex ecosystem where 1014 microorganisms, mainly including bacteria, virus, and fungi coexist and may play several roles in host nutrition, bone mineralization, immune system regulation, xenobiotics metabolism, proliferation of intestinal cells, and protection against pathogens (Gill et al., 2006[21], Seksik and Landman, 2015[43]). Microbiome, like fingerprint, is individual-specific; nevertheless, several factors such as genetics, diet, antibiotic therapy, and environmental changes can alter it (Faith et al., 2013[18]; Lozupone et al., 2012[29]). A healthy state of the gut microbiota may consist of a lower number of pathogenic species such as Campylobacter jejuni, Salmonella enterica, Vibrio cholerae, and a higher number of non-pathogenic genera, including Bacteroides, Prevotella and Ruminococcus (Hollister et al., 2014[22]). A quantitative or qualitative disruption in composition of the normal microbiota is known as ‘gut dysbiosis’ which may adversely affect body metabolism and immune responses. It has recently been suggested that dysbiosis may contribute to the occurrence of NAFLD (Carding et al., 2015[10]).

Recent findings raise concerns about the negative effects of ASs on health. The aim of the present study is to investigate the effects of ASs on the risk of NAFLD. The focus of this review is on microbiota changes and dysbiosis.

Dysbiosis and NAFLD

In recent years, studying the relationship between the microbiota and its potential role in the pathogenesis of NAFLD has been a subject of interest (Saltzman et al., 2018[41]; Kolodziejczyk et al., 2019[26]; Duarte et al., 2019[15]). A growing body of evidence suggests that along with diet, physical activity and genetic predisposition, the gut microbiota affects hepatic metabolism as well as the inflammatory status of the liver. Therefore, microbiota may be involved in development of NAFLD and its progression to NASH (Kolodziejczyk et al., 2019[26]; Duarte et al., 2019[15]). In the following sections, we focus on the studies and mechanisms underlying the impact of dysbiosis on NAFLD pathogenesis. Table 1(Tab. 1) summarizes the mechanisms underlying the impact of dysbiosis on NAFLD.

NAFLD is one of the most important comorbidities of obesity. The gut microbiota has an important role in harvesting energy from the diet and can result in adiposity (Turnbaugh et al., 2006[47]). The underlying mechanisms are improved development of the small intestinal epithelium and impact on the gut physiology and motility (Lichtman et al., 1991[27]). Furthermore metagenomic studies suggest that the gut microbiota in obese mice had a higher potential for harvesting energy (Turnbaugh et al., 2006[47]).

Bacterial components activate Toll-like receptors (TLRs) in the gut mucosa. Transferring the gut microbiota of mice affected by metabolic syndrome into the gut of normal mice resulted in the development of metabolic syndrome in normal mice. This observation supports the crucial role of gut microbiota in the development of metabolic syndrome (Rivera et al., 2007[38]). The healthy intestinal epithelium forms a tightly sealed physical barrier. Dysbiosis disrupts the gut epithelial barrier and increases intestinal permeability. A leaky gut leads to the passage of pro-inflammatory molecules and bacterial endotoxins to bloodstream reaching the liver via the portal vein and increases hepatic inflammation and the susceptibility to NAFLD (Muñoz et al., 2019[33], Cani et al., 2007[9]). Lipopolysaccharides (LPS) produced by gram-negative bacteria lead to insulin resistance through TLR4-dependent activation of the NF-κB pathway and increase inflammation in the liver (Boulange et al., 2016[6]; Cani et al., 2007[9]). Another microbiota-derived mediators related to NAFLD are short-chain fatty acids (SCFAs) (Juárez-Hernández et al., 2016[24]). SCFAs including acid acetic acid, propionic acid, and butyric acid are fatty acids with seven or fewer carbon atoms, mainly produced from indigestible carbohydrate fermentation (Chambers et al., 2018[12]). SCFAs are the main energy source for gut epithelial cells, help to preserve the intestinal integrity, and also have several effects on enery metabolism, immune response, and adipose tissue expansion (Arslan, 2014[4]). Dysbiosis results in an increase of SCFAs that can in turn promote hepatic lipogenesis (mainly by acetate), and gluconeogenesis (mainly by propionate) leading to liver steatosis (Morrison and Preston, 2016[32]). Also, SCFAs regulate the production of several inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), IL-6, and IL-10 that are involved in the pathogenesis of NAFLD (Vinolo et al., 2011[49]). Literature provides evidence of SCFAs potential use as indicator of NAFLD progression (Aragonès et al., 2019[3]). Carbohydrate fermentation by gut microbiota has another by-product, i.e. ethanol, which could promote NAFLD (Zhu et al., 2013[51]). Blood ethanol concentrations are higher in NAFLD patients compared to healthy subjects suggesting that endogenous ethanol production may contribute to the liver damages by increasing several inflammatory signals (Zhu et al., 2016[50]). A metabolite of phenylalanine, phenyl acetate, is another microbiota-derived metabolite that is higher in the blood of NASH patients and is associated with disease severity (Hoyles et al., 2018[23]).

Activation or modulation of bile acid receptors, such as the farnesoid X receptor and TGR5, and transporters, such as the ileal apical sodium-dependent bile acid transporters, are involved in the pathogenesis of insulin resistance and NAFLD. Given that gut microbiota can change the bile acid pool and signaling characteristics, this may be another possible mechanism of dysbiosis-induced NAFLD development (Arab et al., 2017[2]).

The mobilization of liver fat depends on production and transportation of very low density lipoprotein (VLDL). The production of this lipoprotein particle depends on the presence of choline. Choline-free diets are commonly used for NAFLD induction in animals. Absence of choline leads to hepatic fat accumulation that causes oxidative stress and alterations in cytokines and adipokines, as well as slight inflammation and fibrosis in the liver (Al Rajabi et al., 2014[1]; Corbin and Zeisel, 2012[13]). The gut microbiota converts choline to dimethylamine (DMA) and trimethylamine (TMA) which may lead to choline deficiency. Dysbiosis enhances the metabolism of choline to TMA and DMA, thus leading to liver-related consequences (Corbin and Zeisel, 2012[13]).

Artificial Sweeteners and Dysbiosis

Dysbiosis by definition is “an imbalance in the gut microbial community that is associated with disease” (Messer and Chang, 2018[30]). By that definition, it is safe to say that, despite previous misconceptions, some ASs “unequivocally and irrefutably” disrupt gut microbiota (Schiffman and Nagle, 2019[42]). Nonetheless, various AS formulations may have different effects. Moreover, there are several questions regarding the extent and the nature of what happens after consuming certain ASs.

Ruiz-Ojeda et al. (2019[40]) reviewed the then-existing literature on the impact of some FDA-approved ASs on the gut microbiota. Even though in their review they were able to find some relevant data regarding the effect of sucralose and saccharin on the gut microbiota, they could not do the same for other ASs. Based on their findings and also the search that we have conducted, there is scarce information on the effect of other ASs on gut microbiota. Therefore, we discuss sucralose and saccharin in more details.

Sucralose is one of the most widely-consumed ASs around the world. It is 600 times sweeter than sucrose. Studies suggest that sucralose may cause dysbiosis by decreasing the total number of aerobic and anaerobic species, bifidobacteria, lactobacilli, Bacteriodes, and Clostridiales (Ruiz-Ojeda et al., 2019[40]). Another study showed that it could increase Clostridium cluster XIVa in mice (Uebanso et al., 2017[48]).

Saccharin, also one of the most globally-used sweeteners, has been investigated for its possible role in dysbiosis. Current data suggest that saccharin might inhibit the growth of six bacterial strains: three lactobacilli species and three E. coli strains (Ruiz-Ojeda et al., 2019[40]). Another study found that saccharin increases Bacteriodes genus and, similar to the previous study, reduces the number of lactobacilli (Suez et al., 2015[46]).

It needs to be emphasized that there still is a major shortage of original investigations regarding other FDA-approved ASs. Some of them (e.g. neotame, advantame, and cyclamate) have never been examined. Others (e.g. Acesulfame potassium and aspartame) have only been studied to a limited extent; therefore, their impact on the gut microbiota remains unclear and inconclusive.

Another important issue is that most of the existing information is animal-based. There is a significant need to examine this possible association in human subjects with various dietary approaches; due to the fact that in human beings there are a lot of factors affecting the gut microbiota, most importantly the dietary pattern. Suez et al. (2015[46]) suggested that by following a large cohort of human subjects, they were able to find associations between consumption of non-nutritional sweeteners (NNSs) and a disrupted microbiota. However, more studies are required to reproduce this finding and confirm a true causal relationship.

Further studies are required to understand the possible mechanisms by which ASs may alter the composition of the gut microbiota. There have been several ‘assumptions’ though. Suez et al. (2015[46]) proposed that sucralose and saccharin may be metabolized by some genera of bacteria, while remain not metabolizable for the rest. This raised the proposition that the number of the bacteria able to metabolize the consumed AS may rise to the disadvantage of the others. However, at this point, this remains suggestive and needs to be confirmed by further more investigation.

Conclusion

Dysbiosis is one of the factors with demonstrated contribution to the pathogenesis of NAFLD. Increasing evidence shows that ASs have a potential role in microbiota alteration and dysbiosis. We speculate that increased consumption of ASs can further raise the prevalence of NAFLD. However, further human studies are needed to determine this relationship definitively.

Acknowledgements

This study is related to the project no. 20181 from the Student Research Committee, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. We also appreciate the Student Research Committee and Research & Technology Chancellor in SBMU for their financial support of this study.

Conflict of interest

The authors declared that there is no conflict of interest.

Al Rajabi A Castro GS Da Silva RP Nelson RC Thiesen A Vannucchi H Choline supplementation protects against liver damage by normalizing cholesterol metabolism in Pemt/Ldlr knockout mice fed a high-fat diet J Nutr 2014 144 252 257 Arab JP Karpen SJ Dawson PA Arrese M Trauner M Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives Hepatology 2017 65 350 362 Aragonès G González-García S Aguilar C Richart C Auguet T Gut microbiota-derived mediators as potential markers in nonalcoholic fatty liver disease Biomed Res Int 2019 2019 8507583 Arslan N Obesity, fatty liver disease and intestinal microbiota World J Gastroenterol 2014 20 16452 16463 Bhatt HB Smith RJ Fatty liver disease in diabetes mellitus Hepatobil Surg Nutr 2015 4 101 108 Boulange CL Neves AL Chilloux J Nicholson JK Dumas ME Impact of the gut microbiota on inflammation, obesity, and metabolic disease Genome Med 2016 8 42 Browning JD Szczepaniak LS Dobbins R Nuremberg P Horton JD Cohen JC Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity Hepatology 2004 40 1387 1395 Byrne CD Targher G NAFLD: A multisystem disease J Hepatol 2015 62 S47 S64 Cani PD Amar J Iglesias MA Poggi M Knauf C Bastelica D Metabolic endotoxemia initiates obesity and insulin resistance Diabetes 2007 56 1761 1772 Carding S Verbeke K Vipond DT Corfe BM Owen LJ Dysbiosis of the gut microbiota in disease Microb Ecol Health Dis 2015 26 26191 Chalasani N Younossi Z Lavine JE Charlton M Cusi K Rinella M The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases Hepatology 2018 67 328 357 Chambers ES Preston T Frost G Morrison DJ Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health Curr Nutr Rep 2018 7 198 206 Corbin KD Zeisel SH Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression Curr Opin Gastroenterol 2012 28 159 165 Du Plessis J Van Pelt J Korf H Mathieu C Van Der Schueren B Lannoo M Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease Gastroenterology 2015 149 635 48.e14 Duarte SMB Stefano JT Oliveira CP Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) Ann Hepatol 2019 18 416 421 Emamat H Galactose intake is related to nonalcoholic fatty liver disease Nutr Food Sci 2019 49 359 367 Emamat H Foroughi F Eini-Zinab H Hekmatdoost A The effects of onion consumption on prevention of nonalcoholic fatty liver disease Indian J Clin Biochem 2018 33 75 80 Faith JJ Guruge JL Charbonneau M Subramanian S Seedorf H Goodman AL The long-term stability of the human gut microbiota Science 2013 341 1237439 FDA High-intensity sweeteners 2014 Silver Spring, MD U. S. Food & Drug Administration Available from: https://www.fda.gov/food/food-additives-petitions/high-intensity-sweeteners George ES Forsyth A Itsiopoulos C Nicoll AJ Ryan M Sood S Practical dietary recommendations for the prevention and management of nonalcoholic fatty liver disease in adults Adv Nutr 2018 9 30 40 Gill SR Pop M Deboy RT Eckburg PB Turnbaugh PJ Samuel BS Metagenomic analysis of the human distal gut microbiome Science 2006 312 1355 1359 Hollister EB Gao C Versalovic J Compositional and functional features of the gastrointestinal microbiome and their effects on human health Gastroenterology 2014 146 1449 1458 Hoyles L Fernández-Real JM Federici M Serino M Abbott J Charpentier J Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women [published correction appears in Nat Med. 2018 Aug 9;:] Nat Med 2018 24 1070 1080 Juárez-Hernández E Chávez-Tapia NC Uribe M Barbero-Becerra VJ Role of bioactive fatty acids in nonalcoholic fatty liver disease Nutr J 2016 15 72 Ko YH Wong TC Hsu YY Kuo KL Yang SH The correlation between body fat, visceral fat, and nonalcoholic fatty liver disease Metab Syndr Relat Disord 2017 15 304 311 Kolodziejczyk AA Zheng D Shibolet O Elinav E The role of the microbiome in NAFLD and NASH EMBO Mol Med 2019 11 e9302 Lichtman SN Keku J Schwab JH Sartor RB Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline Gastroenterology 1991 100 513 519 Lohner S Toews I Meerpohl JJ Health outcomes of non-nutritive sweeteners: analysis of the research landscape Nutr J 2017 16 55 Lozupone CA Stombaugh JI Gordon JI Jansson JK Knight R Diversity, stability and resilience of the human gut microbiota Nature 2012 489 220 230 Messer JS Chang EB Said HM Microbial physiology of the digestive tract and its role in inflammatory bowel diseases Physiology of the gastrointestinal tract, Vol. 1 2018 6th ed. Amsterdam Elsevier-Academic Press 795–810 Mirmiran P Amirhamidi Z Ejtahed H-S Bahadoran Z Azizi F Relationship between diet and non-alcoholic fatty liver disease: a review article Iran J Public Health 2017 46 1007 1017 Morrison DJ Preston T Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism Gut Microb 2016 7 189 200 Muñoz L Borrero MJ Ubeda M Conde E Del Campo R Rodriguez-Serrano M Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis Hepatology 2019 70 925 938 Musso G Gambino R Cassader M Pagano G Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann Med 2011 43 617 649 Musso G Gambino R Tabibian JH Ekstedt M Kechagias S Hamaguchi M Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis PLoS Med 2014 11 e1001680 Pearlman M Obert J Casey L The association between artificial sweeteners and obesity Curr Gastroenterol Rep 2017 19 64 Polyzos SA Kountouras J Mantzoros CS Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics Metabolism 2019 92 82 97 Rivera CA Adegboyega P Van Rooijen N Tagalicud A Allman M Wallace M Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis J Hepatol 2007 47 571 579 Ruanpeng D Thongprayoon C Cheungpasitporn W Harindhanavudhi T Sugar and artificially sweetened beverages linked to obesity: a systematic review and meta-analysis QJM 2017 110 513 520 Ruiz-Ojeda FJ Plaza-Diaz J Saez-Lara MJ Gil A Effects of sweeteners on the gut microbiota: A review of experimental studies and clinical trials Adv Nutr 2019 10 S31 S48 Saltzman ET Palacios T Thomsen M Vitetta L Intestinal microbiome shifts, dysbiosis, inflammation, and non-alcoholic fatty liver disease Front Microbiol 2018 9 61 Schiffman SSS Nagle HT Revisited: Assessing the in vivo data on low/no-calorie sweeteners and the gut microbiota Food Chem Toxicol 2019 132 110692 Seksik P Landman C Understanding microbiome data: A primer for clinicians Dig Dis 2015 33 Suppl 1 11 16 Shallenberger RS Acree TE Beidler LM Chemical structure of compounds and their sweet and bitter taste Taste 1971 Berlin, Heidelberg Springer-Verlag 221 277 Handbook of sensory physiology,Vol. IV Stanhope KL Sugar consumption, metabolic disease and obesity: The state of the controversy Crit Rev Clin Lab Sci 2016 53 52 67 Suez J Korem T Zilberman-Schapira G Segal E Elinav E Non-caloric artificial sweeteners and the microbiome: findings and challenges Gut Microb 2015 6 149 155 Turnbaugh PJ Ley RE Mahowald MA Magrini V Mardis ER Gordon JI An obesity-associated gut microbiome with increased capacity for energy harvest Nature 2006 444 1027 1031 Uebanso T Ohnishi A Kitayama R Yoshimoto A Nakahashi M Shimohata T Effects of low-dose non-caloric sweetener consumption on gut microbiota in mice Nutrients 2017 9 560 Vinolo MA Rodrigues HG Nachbar RT Curi R Regulation of inflammation by short chain fatty acids Nutrients 2011 3 858 876 Zhu L Baker RD Zhu R Baker SS Gut microbiota produce alcohol and contribute to NAFLD Gut 2016 65 1232 Zhu L Baker SS Gill C Liu W Alkhouri R Baker RD Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH Hepatology 2013 57 601 609 The mechanisms underlying the impact of dysbiosis on NAFLD